CLAIMS

1. Use of azasetron or an analog of azasetron, or a pharmaceutically acceptable salt and/or solvate thereof, for the manufacture of a medicament for the preservation of residual hearing following insertion of a cochlear implant in a subject in need thereof, wherein the subject has a hearing threshold at baseline in at least one ear corresponding to an unaided audiometric threshold at baseline greater than 65 dB, the unaided audiometric threshold being expressed as the average of at least 3 values each determined at a different frequency within the range from 0.25 kHz to 0.75 kHz.

2. The use according to claim **1**, wherein the unaided audiometric threshold is expressed as the average of the values determined at 0.25 kHz, 0.5 kHz and 0.75 kHz.

3. The use according to claim **1** or **2**, wherein the unaided audiometric threshold is unaided pure-tone average (PTA).

4. The use according to any one of claims **1** to **3**, wherein the pharmaceutically acceptable salt is selected from a besylate salt, a malate salt, and a hydrochloride salt.

5. The use according to any one of claims **1** to **4**, wherein azasetron is (*R*)-azasetron, (*S*)-azasetron, a mixture thereof, or a pharmaceutically acceptable salt and/or solvate thereof.

6. The use according to any one of claims **1** to **5**, wherein azasetron is (*R*)-azasetron or a pharmaceutically acceptable salt and/or solvate thereof.

7. The use according to any one of claims **1** to **6**, wherein the pharmaceutically acceptable salt of azasetron is (*R*)-azasetron besylate.

8. The use according to any one of claims **1** to **4**, wherein the analog of azasetron is a benzoxazine compound or a pharmaceutically acceptable salt and/or solvate thereof.

9. The use according to claim **8**, wherein the benzoxazine compound is selected from 6-chloro-3,4-dihydro-2-methyl-3-oxo-N-(3-quinuclidinyl)-2H-1,4-benzoxazine-8-carboxamide, 6-chloro-3,4-dihydro-2,4-dimethyl-3-oxo-N-(3-quinuclidinyl)-2H-benzoxazine-8-carboxamide, 6-chloro-2-ethyl-3,4-dihydro-4-methyl-3-oxo-N-(3-quinuclidinyl)-2H-1,4-benzoxazine-8-carboxamide, 6-bromo-3,4-dihydro-2,4-dimethyl-3-oxo-N-(3-quinuclidinyl)-2H-1,4-benzoxazine-8-carboxamide, and 6-chloro-3,4-dihydro-2,2,4-trimethyl-3-oxo-N-(3-quinuclidiny-l)-2H-1,4-benzoxazine-8-carboxamide.

10. The use according to any one of claims **1** to **9**, wherein azasetron or the analog of azasetron, or the pharmaceutically acceptable salt and/or solvate thereof, is for administration at a daily dose ranging from about 20 mg to about 200 mg.

11. The use according to any one of claims **1** to **9**, wherein azasetron or the analog of azasetron, or the pharmaceutically acceptable salt and/or solvate thereof, is for administration at a daily free base equivalent dose of about 40 mg or of about 60 mg.

12. The use according to any one of claims **1** to **11**, wherein azasetron or the analog of azasetron, or the pharmaceutically acceptable salt and/or solvate thereof, is for oral administration.

13. The use according to any one of claims **1** to **11**, wherein azasetron or the analog of azasetron, or the pharmaceutically acceptable salt and/or solvate thereof, is for local administration.

14. The use according to any one of claims **1** to **13**, wherein azasetron or the analog of azasetron, or the pharmaceutically acceptable salt and/or solvate thereof, is for administration from at least 3 days prior to insertion of the cochlear implant.